Jann N. Sarkaria

Nov 1, 2024 | healio.com | Matthew Shinkle |Mindy Valcarcel |Jann N. Sarkaria

You've successfully added Neuro-Oncology to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: The 3.3-month improvement in median OS in the investigational arm did not reach statistical significance. Researchers characterized the combination as well tolerated.

Oct 31, 2024 | jamanetwork.com | Jann N. Sarkaria |Karla V. Ballman |Sani H. Kizilbash

Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial Key PointsQuestion  Does the polyadenosine diphosphate-ribose polymerase (PARP) inhibitor veliparib enhance the efficacy of temozolomide in patients with newly diagnosed, MGMT promoter hypermethylated glioblastoma?